Dublin, Oct. 04, 2017 -- The "Cell Therapy - Technologies, Markets and Companies" report from Jain PharmaBiotech has been added to Research and Markets' offering.
This report describes and evaluates cell therapy technologies and methods, which have already started to play an important role in the practice of medicine. Hematopoietic stem cell transplantation is replacing the old fashioned bone marrow transplants. Role of cells in drug discovery is also described. Cell therapy is bound to become a part of medical practice.
Stem cells are discussed in detail in one chapter. Some light is thrown on the current controversy of embryonic sources of stem cells and comparison with adult sources. Other sources of stem cells such as the placenta, cord blood and fat removed by liposuction are also discussed. Stem cells can also be genetically modified prior to transplantation.
Cell therapy technologies overlap with those of gene therapy, cancer vaccines, drug delivery, tissue engineering and regenerative medicine. Pharmaceutical applications of stem cells including those in drug discovery are also described. Various types of cells used, methods of preparation and culture, encapsulation and genetic engineering of cells are discussed. Sources of cells, both human and animal (xenotransplantation) are discussed. Methods of delivery of cell therapy range from injections to surgical implantation using special devices.
Cell therapy has applications in a large number of disorders. The most important are diseases of the nervous system and cancer which are the topics for separate chapters. Other applications include cardiac disorders (myocardial infarction and heart failure), diabetes mellitus, diseases of bones and joints, genetic disorders, and wounds of the skin and soft tissues.
Regulatory and ethical issues involving cell therapy are important and are discussed. Current political debate on the use of stem cells from embryonic sources (hESCs) is also presented. Safety is an essential consideration of any new therapy and regulations for cell therapy are those for biological preparations.
The cell-based markets was analyzed for 2016, and projected to 2026.The markets are analyzed according to therapeutic categories, technologies and geographical areas. The largest expansion will be in diseases of the central nervous system, cancer and cardiovascular disorders. Skin and soft tissue repair as well as diabetes mellitus will be other major markets.
The number of companies involved in cell therapy has increased remarkably during the past few years. More than 500 companies have been identified to be involved in cell therapy and 307 of these are profiled in part II of the report along with tabulation of 291 alliances. Of these companies, 170 are involved in stem cells. Profiles of 72 academic institutions in the US involved in cell therapy are also included in part II along with their commercial collaborations. The text is supplemented with 64 Tables and 22 Figures. The bibliography contains 1,200 selected references, which are cited in the text.
Key Topics Covered:
Part I: Technologies, Ethics & Regulations
Executive Summary
1. Introduction to Cell Therapy
2. Cell Therapy Technologies
3. Stem Cells
4. Clinical Applications of Cell Therapy
5. Cell Therapy for Cardiovascular Disorders
6. Cell Therapy for Cancer
7. Cell Therapy for Neurological Disorders
8. Ethical, Legal and Political Aspects of Cell therapy
9. Safety and Regulatory Aspects of Cell Therapy
Part II: Markets, Companies & Academic Institutions
10. Markets and Future Prospects for Cell Therapy
11. Companies Involved in Cell Therapy
12. Academic Institutions
13. References
For more information about this report visit https://www.researchandmarkets.com/research/jh9b6q/cell_therapy
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Genomics


California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics
Winter Storm Disrupts Northeast Travel as Snow and Ice Blanket New York, New Jersey
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 



